Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution™ (eGMS™) have been selected as poster presentations at the International Hospital Diabetes Meeting (IHDM), taking place from May 8-9th in San Francisco. Hosted by the Diabetes Technology Society, the fifth annual IHDM conference will showcase the optimal use of future and current technologies for people with diabetes in both critical and non-critical care settings.
“Our series of studies demonstrate how Glytec’s eGMS provides better blood glucose control over traditional methods of insulin management for both subcutaneous and IV dosing,” said Joseph Aloi, MD, Chief, Section on Endocrinology and Metabolism at Wake Forest University Medical Center and formerly Clinical Director at East Virginia Medical School Strelitz Diabetes Center. “In addition, we achieved these improved results while simultaneously experiencing minimal to rare hypoglycemic events.”
Detailing best practices for improved IV insulin management, the following posters will be presented at IHDM by Dr. Joseph Aloi; Dr. Paul Chidester, Vice President of Medical Affairs at Sentara Healthcare; and Amy Henderson, RN, BSN, Clinical Solutions Consultant at Glytec:
- “Use of eGlycemic Management Solution by Glytec Provides Safe and Effective Meal Coverage for CV Patients Managed on IV Insulin Therapy” – In a study using Glytec’s eGMS for meal coverage, patients achieved a significant number of target blood glucose values, regardless of the blood glucose target range and time frame (pre-, during-, or post-meal), with no incidence of critical hypoglycemia.
- “Use of eGlycemic Management Solution by Glytec Achieves Glucose Targets for Pediatric DKA Patients Safely” – This poster highlights how Glytec’s IV eGMS helped pediatric diabetic ketoacidosis (DKA) patients achieve a safe time to target, glucose velocity drop, and with very low incidence of hypoglycemia.
- “Use of eGlycemic Management Solution by Glytec Provides Safe and Effective Glucose Control for Cardiac Surgery Patients Managed on IV Insulin Therapy” – Research findings demonstrate automated, predictive IV and SubQ insulin dosing achieved target blood glucose values regardless of measurement timeframe.
Furthermore, Dr. Melanie Mabrey, Vice President of Clinical Practice at Glytec, and Dr. Andrew S. Rhinehart, Chief Medical Officer at Glytec, will be presenting the following posters to showcase improvements that can be made through the use of Glytec’s eGMS for subcutaneous (SubQ) glycemic management:
- “Use of eGlycemic Management Solution by Glytec Produces Less Hypoglycemia for Patients Managed on Subcutaneous Insulin Therapy.” – Results show patients using Glytec’s eGMS for subcutaneous insulin dosing achieved improved glycemic control with lower incidence of hypoglycemia compared to traditional insulin dosing methods.
- “Use of eGlycemic Management Solution by Glytec Achieved ADA Glycemic Targets with Low Hypoglycemia for Patients Managed on Subcutaneous Insulin Therapy” – Study findings detail how Glytec’s SubQ eGMS can maintain glucose control within ADA recommended targets, including at mealtime and bedtime, without increased risk of hypoglycemia.
- “Use of eGlycemic Management Solution by Glytec to Identify, Treat and Improve Glycemic Care for CHF Patients” – These research results detail that, with automated surveillance, Glytec’s eGMS can safely identify hyperglycemia in chronic heart failure (CHF) patients to improve glucose control. Identified patients reached prescribed glycemic target with very low incidence of hypoglycemia.
“Having been a Glytec customer and physician-user prior to joining the company, l have witnessed first-hand the positive results that can be achieved by leveraging Glytec’s eGMS,” said Dr. Rhinehart. “It is our mission to help people achieve better glycemic control across the care continuum and these studies showcase that automated, predictive insulin dosing algorithms are setting a new standard.”